Table S1—Clinical characteristics, ancillary test results, and sleep symptoms in our Creutzfeldt-Jakob disease cohort.

| Patient ID | Age – Sex | Clinical Signs and Symptoms | CSF Biomarkers (tau in pg/mL) | Typical MRI | EEG PSWC | Biochemical Subtype | Sleep Signs and Symptoms | BMI |
|---------------|-------------|-----------------------------|----------------------------------|----------------|-------------|------------------------|-----------------------------|-----|
| 1 | 66 – Female | RPD; C; P/E; AM; M | Tau = 440; 14-3-3 - | N/A | - | MV1-2 | Н | N/A |
| 2 | 76 – Male | RPD; AM; HC | N/A | + | + | MM1 | None | 42 |
| 3 | 61 – Female | RPD; C | Tau = 4,692; 14-3-3 + | + | - | VV1-2 | I | 31 |
| 4 | 60 – Male | RPD; C; P/E; M | Tau = 3,371; 14-3-3 + | N/A | - | VV1-2 | PLM; P | 37 |
| 5 | 61 – Male | RPD; C; V; M; HC | N/A | + | - | MM1 | H; I; P | 25 |
| 6 | 60 – Female | RPD; C; P/E; AM; M | Tau = 9,324; 14-3-3 + | + | + | MM1 | PLM | 26 |
| 7 | 70 – Female | RPD; C; P/E; M; HC | Tau = 2,170; 14-3-3 + | + | - | MM1 | I | 24 |
| 8 | 74 – Male | RPD; C; P/E; AM; V; M; HC | Tau = 2,029; 14-3-3 + | + | - | PSPr-VV | H; P | 21 |
| 9 | 68 – Female | RPD; C; P/E; V; HC | Tau = 2,371; 14-3-3 - | + | + | MM2 | Н | 32 |
| 10 | 46 – Male | RPD; C; P/E; AM; V; M | Tau = 6,230; 14-3-3 + | + | + | E200K-MM | None | 17 |
| 11 | 52 – Male | RPD; P/E; AM | Tau = 5,373; 14-3-3 + | + | - | MM1 | PLM | 30 |
| 12 | 61 – Male | RPD; C; P/E; HC | N/A | + | + | MM1 | I | 42 |
| 13 | 66 – Female | RPD; C; P/E; AM; V | Tau = 8,155; 14-3-3 - | + | N/A | MM1 | None | 25 |
| 14 | 72 – Female | RPD; C; P/E; V; M | Tau = 3,135; 14-3-3 + | - | - | MM1 | I | 39 |
| 15 | 61 – Female | RPD; C; P/E; AM; M | Tau = 9,157; 14-3-3 + | + | + | MM1 | Н | 24 |
| 16 | 53 – Female | RPD; C; P/E; AM; M; HC | Tau = 4,743; 14-3-3 + | + | + | MM1 | I; P | 44 |
| 17 | 63 – Male | RPD; C; P/E | Tau = 702; 14-3-3 - | + | - | MV1-2 | H; PLM | 26 |
| 18 | 68 – Male | RPD; C; P/E; M | Tau = 5,760; 14-3-3 + | + | - | VV1-2 | P | 35 |
| 19 | 52 – Female | RPD; C; P/E; HC | Tau = 792; 14-3-3 - | + | + | MM2 | Н | 33 |
| 20 | 62 – Female | RPD; C; P/E; AM; M; HC | Tau = 3,879; 14-3-3 + | + | + | MM1 | H; I | N/A |
| 21 | 68 – Male | RPD; ; P/E; AM; M; HC | Tau = 1,069; 14-3-3 - | N/A | - | MM1-2 | H; P | 22 |
| 22 | 70 – Male | RPD; ; P/E; M; HC | Tau = 4,223; 14-3-3 + | + | + | MM1 | H; PLM | 28 |
| 23 | 74 – Male | RPD; C; P/E | Tau = 5,642; 14-3-3 + | - | - | VV2 | I | 22 |
| 24 | 42 – Male | RPD; C; P/E; M | Tau = 1,691; 14-3-3 - | + | - | VV1 | I; PLM; P | 24 |
| 25 | 73 – Female | RPD; C; P/E; M | Tau = 2,701; 14-3-3 - | + | - | MV1-2 | I; PLM | 38 |
| 26 | 61 – Male | RPD; C; P/E; M | Tau = 2,128; 14-3-3 + | + | - | MV1-2 | H; I; P | 31 |
| 27 | 58 – Female | RPD; C; P/E | N/A | + | - | E200K-MV | I; P | 22 |
| 28 | 63 – Male | RPD; C; P/E; V; M | Tau = 2,818; 14-3-3 + | + | - | VV2 | I | 29 |

AM, akinetic mutism; BMI, body mass index; C, cerebellar; CSF, cerebrospinal fluid; EEG, electroencephalogram; H, hypersomnia; HC, high cortical; I, insomnia; M, myoclonus; MRI, magnetic resonance imaging; P, parasomnia; P/E, pyramidal/extrapyramidal; PLM, periodic limb movements; PSG, polysomnogram; PSWC, periodic sharp wave complexes; RPD, rapidly progressive dementia; V, visual.

Table S2—PSWC on routine electroencephalography compared with PSWC on electroencephalography during polysomnography.

| | PSG PSWC Present | PSG PSWC Absent |
|--------------------------|------------------|-----------------|
| Routine EEG PSWC Present | 2 | 3 |
| Routine EEG PSWC Absent | 0 ^a | 7 |

^aTwo patients who underwent PSG did not have full montage EEG performed during their studies. EEG, electroencephalography; PSG, polysomnography; PSWC, positive sharp wave complexes.